BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32271809)

  • 41. Size-selective enrichment of N-linked glycans using highly ordered mesoporous carbon material and detection by MALDI-TOF MS.
    Qin H; Zhao L; Li R; Wu R; Zou H
    Anal Chem; 2011 Oct; 83(20):7721-8. PubMed ID: 21899340
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual isotopic labeling combined with fluorous solid-phase extraction for simultaneous discovery of neutral/sialylated N-glycans as biomarkers for gastric cancer.
    Wang L; Yang L; Zhang Y; Lu H
    Anal Chim Acta; 2020 Apr; 1104():87-94. PubMed ID: 32106961
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum N-glycome characterization and anti-carbohydrate antibody profiling in oral squamous cell carcinoma patients.
    Guu SY; Lin TH; Chang SC; Wang RJ; Hung LY; Fang PJ; Tang WC; Yu P; Chang CF
    PLoS One; 2017; 12(6):e0178927. PubMed ID: 28594851
    [TBL] [Abstract][Full Text] [Related]  

  • 44. N-glycan profiling of papillary thyroid carcinoma tissues by MALDI-TOF-MS.
    Koçak ÖF; Kayili HM; Albayrak M; Yaman ME; Kadıoğlu Y; Salih B
    Anal Biochem; 2019 Nov; 584():113389. PubMed ID: 31400301
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS.
    Matsumoto K; Shimizu C; Arao T; Andoh M; Katsumata N; Kohno T; Yonemori K; Koizumi F; Yokote H; Aogi K; Tamura K; Nishio K; Fujiwara Y
    J Proteome Res; 2009 Feb; 8(2):457-62. PubMed ID: 19140672
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics.
    Provatopoulou X; Georgiou GP; Kalogera E; Kalles V; Matiatou MA; Papapanagiotou I; Sagkriotis A; Zografos GC; Gounaris A
    BMC Cancer; 2015 Nov; 15():898. PubMed ID: 26560078
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients.
    Pierce A; Saldova R; Abd Hamid UM; Abrahams JL; McDermott EW; Evoy D; Duffy MJ; Rudd PM
    Glycobiology; 2010 Oct; 20(10):1283-8. PubMed ID: 20581008
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of a hydrophilic interaction liquid chromatography coupled with matrix-assisted laser desorption/ionization-mass spectrometric imaging platform for N-glycan relative quantitation using stable-isotope labeled hydrazide reagents.
    Chen Z; Zhong X; Tie C; Chen B; Zhang X; Li L
    Anal Bioanal Chem; 2017 Jul; 409(18):4437-4447. PubMed ID: 28540462
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative glycomic profiling in esophageal adenocarcinoma.
    Hammoud ZT; Mechref Y; Hussein A; Bekesova S; Zhang M; Kesler KA; Novotny MV
    J Thorac Cardiovasc Surg; 2010 May; 139(5):1216-23. PubMed ID: 20412957
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis.
    Kamiyama T; Yokoo H; Furukawa J; Kurogochi M; Togashi T; Miura N; Nakanishi K; Kamachi H; Kakisaka T; Tsuruga Y; Fujiyoshi M; Taketomi A; Nishimura S; Todo S
    Hepatology; 2013 Jun; 57(6):2314-25. PubMed ID: 23322672
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MALDI Mass Spectrometry Imaging of N-Linked Glycans in Cancer Tissues.
    Drake RR; Powers TW; Jones EE; Bruner E; Mehta AS; Angel PM
    Adv Cancer Res; 2017; 134():85-116. PubMed ID: 28110657
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detecting glycan cancer biomarkers in serum samples using MALDI FT-ICR mass spectrometry data.
    Barkauskas DA; An HJ; Kronewitter SR; de Leoz ML; Chew HK; de Vere White RW; Leiserowitz GS; Miyamoto S; Lebrilla CB; Rocke DM
    Bioinformatics; 2009 Jan; 25(2):251-7. PubMed ID: 19073586
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimizing of MALDI-ToF-based low-molecular-weight serum proteome pattern analysis in detection of breast cancer patients; the effect of albumin removal on classification performance.
    Pietrowska M; Marczak L; Polanska J; Nowicka E; Behrent K; Tarnawski R; Stobiecki M; Polanski A; Widlak P
    Neoplasma; 2010; 57(6):537-44. PubMed ID: 20845992
    [TBL] [Abstract][Full Text] [Related]  

  • 54. N-glycans in liver-secreted and immunoglogulin-derived protein fractions.
    Bekesova S; Kosti O; Chandler KB; Wu J; Madej HL; Brown KC; Simonyan V; Goldman R
    J Proteomics; 2012 Apr; 75(7):2216-24. PubMed ID: 22326963
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Integrating age, BMI, and serum N-glycans detected by MALDI mass spectrometry to classify suspicious mammogram findings as benign lesions or breast cancer.
    Blaschke CRK; Hill EG; Mehta AS; Angel PM; Laronga C; Drake RR
    Sci Rep; 2022 Dec; 12(1):20801. PubMed ID: 36460712
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Abnormal Galactosylated-Glycans recognized by Bandeiraea Simplicifolia Lectin I in saliva of patients with breast Cancer.
    Yang J; Liu X; Shu J; Hou Y; Chen M; Yu H; Ma T; Du H; Zhang J; Qiao Y; He J; Niu L; Yang F; Li Z
    Glycoconj J; 2020 Jun; 37(3):373-394. PubMed ID: 32103424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alternations of N-glycans recognized by Phaseolus vulgaris leucoagglutinin in the saliva of patients with breast cancer.
    Yang J; Ma T; Yu H; Yin M; Qiao Y; Niu L; Yang F; He J; Li Z
    Neoplasma; 2021 Sep; 68(5):994-1004. PubMed ID: 34374293
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach.
    Kadowaki M; Sangai T; Nagashima T; Sakakibara M; Yoshitomi H; Takano S; Sogawa K; Umemura H; Fushimi K; Nakatani Y; Nomura F; Miyazaki M
    J Cancer Res Clin Oncol; 2011 Jul; 137(7):1105-15. PubMed ID: 21253761
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of N- and O-linked glycans recognized by AAL in saliva of patients with atrophic gastritis and gastric cancer.
    Shu J; Yu H; Du H; Zhang J; Zhang K; Li X; Xie H; Li Z
    Cancer Biomark; 2018; 22(4):669-681. PubMed ID: 29865036
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer.
    Zhao YP; Zhou PT; Ji WP; Wang H; Fang M; Wang MM; Yin YP; Jin G; Gao CF
    Clin Exp Med; 2017 Feb; 17(1):9-18. PubMed ID: 26714469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.